Case Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke’s immune-osseous dysplasia
Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021. However, it is rarely used in pediatric patients worldwide....
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521763/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|